Online inquiry

IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3262MR)

This product GTTS-WQ3262MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Lombar radicular pain research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3262MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15003MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ15662MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ3497MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ13143MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ3533MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ1708MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ10569MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ11597MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW